Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap

By Keith Speights - Oct 13, 2017 at 6:02AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This clinical-stage biopharma stock has a great risk-reward proposition.

If 2017 ended today, Aurinia Pharmaceuticals ( AUPH 2.57% ) would rank as one of the biggest winners of the year among biopharmaceutical stocks. Aurinia's share price has more than tripled so far this year.

Is Aurinia overpriced after such tremendous gains? Some might think so. The stock has basically treaded water over the past six months after starting off the year with a roar. However, Aurinia stock is still dirt cheap, in my view, for a couple of key reasons. 

Jigsaw piece with price printed on it next to matching hole with value printed

Image source: Getty Images.

Its lead candidate looks fantastic

You can look over Aurinia's pipeline in detail in less than five seconds. That's because there's only one candidate: experimental lupus nephritis drug voclosporin. But what Aurinia's pipeline lacks in quantity, it makes up for in quality.

Aurinia reported results from a phase 2 study evaluating voclosporin in treating lupus nephritis (LN) in March. And those results were fantastic. After 48 weeks of treatment, 49% of patients receiving a twice-per-day combination of voclosporin with the current standard of care for LN, mycophenolate mofetil, experienced complete remission. Partial remission came for 69% of patients taking the voclosporin combo.

But what about potential safety issues? Voclosporin looked pretty good on that front also. Granted, there were some adverse events. However, nothing unusual popped up that wasn't typical of other immunomodulators. There were nearly as many adverse events in the control group of patients receiving placebo as there were among the patients receiving voclosporin. That's not surprising, considering the severity of LN. Most important, Aurinia reported no treatment-related adverse events leading to death.

It's fair to say that the results for voclosporin were the most encouraging of any drug targeting LN to date. Bristol-Myers Squibb's ( BMY 0.91% ) Orencia failed in a late-stage study for treating the disease. So did Roche's ( RHHBY 0.77% ) Rituxan. Roche also halted a phase 3 study of Ocrevus in treating LN because of a high rate of serious infections. 

There's a huge unmet need

Because of all these past clinical flops, there is still no therapy approved in the U.S. or in Europe for LN. The disease is a serious progression of systemic lupus erythematosus (SLE), commonly referred to as lupus. More than 500,000 Americans, primarily women, are affected by lupus. The disease occurs when the body's immune system attacks its own tissues, causing inflammation. Lupus nephritis, a severe inflammation of the kidneys, develops in as many as 60% of patients with lupus.

And it's a deadly disease. Only 13% of LN patients who don't go on dialysis and don't experience remission of the disease survive for 10 years or more. However, 92% of patients who have complete remission survive for at least 10 years without requiring dialysis. 

In addition to its medical consequences, there are significant financial consequences for LN as well. The average annual medical costs of LN per patient can be up to close to $60,000. That's more expensive than the average annual costs per patient of asthma, hypertension, and COPD combined.

Putting it all together

Combine a disease with a huge unmet need and no approved treatments with a drug that could be the most effective ever at treating the disease, and you have the recipe for a biopharmaceutical success story. Cantor Fitzgerald analyst Elmer Piros thinks voclosporin could achieve peak annual sales of $1.6 billion.

Yet Aurinia Pharmaceuticals has a market cap of only around $530 million. What gives? I get that investors are probably just playing the probability game. Around 40% of drugs in late-stage studies succeed. Of those that do succeed, another 15% don't win regulatory approval. Even when drugs do win approval, it can take years to reach peak sales levels. 

But even factoring in those probabilities, I think Aurinia stock is attractively valued. If the company has positive results in its late-stage study, Aurinia's valuation could easily double from where it is now. That could be a pessimistic view if the company becomes an acquisition target for a big pharma like Bristol-Myers Squibb.

It's possible, of course, that voclosporin will flop in phase 3, as several drugs before it have. However, based on the phase 2 results, my hunch is that it won't. I like the risk-reward proposition with Aurinia and continue to think that this high-flying stock is still dirt cheap.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurinia Pharmaceuticals Inc. Stock Quote
Aurinia Pharmaceuticals Inc.
$19.15 (2.57%) $0.48
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$56.83 (0.91%) $0.51
Roche Holding AG Stock Quote
Roche Holding AG
$49.73 (0.77%) $0.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.